8-K: Avalo Therapeutics Highlights AVTX-009 Potential in Hidradenitis Suppurativa and Provides Corporate Update

Avalo Therapeutics presents an updated investor presentation focusing on AVTX-009, a potential best-in-disease treatment for hidradenitis suppurativa (HS), with topline Phase 2 LOTUS trial data expected in 2026 and a cash runway into at least 2027.

Summary

• Avalo Therapeutics has released an updated investor presentation on May 8, 2025.
• The presentation highlights AVTX-009, an anti-IL-1 mAb, as a potential treatment for hidradenitis suppurativa (HS).
• AVTX-009 has a 15x higher affinity and a longer half-life than lutikizumab.
• The Phase 2 LOTUS trial in HS has been initiated, with topline data expected in 2026.
• The company expects its current cash runway to last into at least 2027.
• HS market is projected to grow to over $10 billion by 2035.
• As of March 31, 2025, Avalo had approximately $125 million in cash.
• The company's adjusted market capitalization is $284.5 million, based on an adjusted share count of 35.5 million and a stock price of $8.01.

Sentiment

Score: 7

Explanation: The document presents a positive outlook for Avalo Therapeutics, highlighting the potential of AVTX-009 and the growing market for HS treatments. The company's strong cash position and experienced management team further contribute to a favorable sentiment.

Positives

• AVTX-009 has a potentially superior profile compared to lutikizumab due to its higher affinity and longer half-life.
• The company has a proven track record of successful leadership, product development, and commercialization.
• The company has a strong cash position with an expected runway into at least 2027.
• The HS market is expected to grow significantly, presenting a large market opportunity.
• AVTX-009 has potential for indication expansion into other immune-mediated diseases.

Risks

• The forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ.
• These risks include drug development costs, timing of trial results, reliance on investigators, enrollment of patients in clinical trials, regulatory risks, and general economic and market risks.
• The company relies on key personnel.
• The war in Ukraine and the Middle East could impact general economic and market risks and uncertainties.

Future Outlook

Avalo anticipates topline data from the Phase 2 LOTUS trial in 2026 and plans to initiate a pivotal program in 2027. The company expects its current cash runway to last into at least 2027.

Industry Context

The presentation positions AVTX-009 as a potential competitor to AbbVie's lutikizumab and other market leaders in the HS treatment landscape, emphasizing its potential for higher efficacy and more convenient dosing. The growing HS market and increasing recognition of the disease suggest a favorable environment for new therapies.

Comparison to Industry Standards

• The document compares AVTX-009 to AbbVie's lutikizumab, highlighting AVTX-009's 15x higher affinity and longer half-life.
• It also references clinical trial data for other HS treatments like bimekizumab and adalimumab to contextualize the potential efficacy of AVTX-009.
• The presentation mentions the CANTOS study (Novartis) to support the effect of IL-1 in reducing total hip/total knee replacements in OA patients with high systemic CRP.
• The presentation mentions the CANTOS study (Novartis) to support anti-IL-1 in reducing the risk of major CV events in patients with previous MI and elevated CRP.

Stakeholder Impact

• Shareholders may benefit from the potential success of AVTX-009 and the company's growth in the HS market.
• Patients with HS could benefit from a new and potentially more effective treatment option.
• Employees may benefit from the company's growth and success.

Next Steps

• Enrollment of first patient in Phase 2 LOTUS trial in 2H 2024.
• Topline data readout from Phase 2 LOTUS trial expected in 2026.
• Initiation of pivotal program in 2027.

Key Dates

Keywords

AVTX-009, hidradenitis suppurativa, HS, IL-1, Avalo Therapeutics, LOTUS trial, investor presentation, immune-mediated inflammatory diseases